



**ISPOR 7th Asia-Pacific
Conference**

3-6 September, 2016
Suntec Singapore Convention &
Exhibition Center
Singapore



Pharmacoeconomics and Outcomes Research in Asia-Pacific: Challenges, Opportunities, and Future Direction

Sunday Research Poster Presentations

Poster Display Hours – 12:30 PM - 7:30 PM

Poster Author Discussion Hour – 6:30 PM - 7:30 PM

POSTER PRESENTATIONS:

PHP:	HEALTH CARE USE & POLICY STUDIES	ROWS A-N
PGI:	GASTROINTESTINAL DISORDERS	ROWS N-O
PMH:	MENTAL HEALTH	ROWS O-R
PSS:	SENSORY SYSTEMS DISORDERS	ROWS R-S
PUK	URINARY/KIDNEY DISORDERS	ROWS S-T

Research Poster Presentations

Acceptance Code	PDF Page #	Topic – Subtopic
PHP1-PHP3	21	Health Care Use & Policy Studies - Consumer Role in Health Care
PHP4-PHP26	22	Health Care Use & Policy Studies - Drug/Device/Diagnostic Use & Policy
PHP27-PHP29	31	Health Care Use & Policy Studies - Equity and Access
PHP30-PHP32	33	Health Care Use & Policy Studies - Formulary Development
PHP33-PHP73	34	Health Care Use & Policy Studies - Health Care Costs & Management
PHP74-PHP105	51	Health Care Use & Policy Studies - Health Care Research & Education
PHP106-PHP115	63	Health Care Use & Policy Studies - Health Technology Assessment Programs
PHP116-PHP117	68	Health Care Use & Policy Studies - Population Health
PHP118-PHP121	69	Health Care Use & Policy Studies - Prescribing Behavior & Treatment Guidelines
PHP122-PHP123	70	Health Care Use & Policy Studies - Quality of Care
PHP124-PHP125	71	Health Care Use & Policy Studies - Regulation of Health Care Sector
PHP126-PHP129	72	Health Care Use & Policy Studies - Risk Sharing/Performance-Based Agreements
PHP130-PHP136	74	Health Care Use & Policy Studies - Conceptual Papers
PGI1-PGI2	76	Gastrointestinal Disorders - Clinical Outcomes Studies
PGI3-PGI6	77	Gastrointestinal Disorders - Cost Studies
PGI7-PGI9	79	Gastrointestinal Disorders - Patient-Reported Outcomes & Patient Preference Studies
PGI10-PGI15	80	Gastrointestinal Disorders - Health Care Use & Policy Studies
PMH1-PMH7	82	Mental Health - Clinical Outcomes Studies
PMH8-PMH16	85	Mental Health - Cost Studies
PMH17-PMH22	89	Mental Health -Reported Outcomes & Patient Preference Studies
PMH23-PMH26	91	Mental Health - Health Care Use & Policy Studies
PSS1-PSS	93	Sensory Systems Disorders - Clinical Outcomes Studies
PSS2-PSS4	93	Sensory Systems Disorders - Cost Studies
PSS5-PSS9	95	Sensory Systems Disorders - Patient-Reported Outcomes & Patient Preference Studies
PSS10-PSS11	97	Sensory Systems Disorders - Health Care Use & Policy Studies
PUK1-PUK3	98	Urinary/Kidney Disorders - Clinical Outcomes Studies
PUK4-PUK8	99	Urinary/Kidney Disorders - Cost Studies
PUK9-PUK13	101	Urinary/Kidney Disorders - Patient-Reported Outcomes & Patient Preference Studies
PUK14-PUK16	103	Urinary/Kidney Disorders - Health Care Use & Policy Studies

HEALTH CARE USE & POLICY STUDIES

HEALTH CARE USE & POLICY STUDIES - Consumer Role in Health Care

- PHP1 A1 **SELF-MEDICATION WITH ANTIBIOTICS IN SANA'A CITY**
Albawani S, **Gnanasan S**, Abd. Aziz N, Hassan Y, Universiti Teknologi MARA, Puncak Alam, Malaysia
- PHP2 A2 **SCHOOLS' PERSPECTIVE ON PROMOTING RATIONAL USE OF ANTIBIOTICS IN NEW DELHI, INDIA – A QUALITATIVE STUDY**
Kotwani A, Holloway K, WHO-SEARO, New Delhi, India
- PHP3 A3 **COMPARISON OF PERCEPTION TOWRDS GENERIC MEDICINES BETWEEN FINAL YEAR PHARMACY AND MEDICAL STUDENTS IN SOUTHEAST YEMEN**
AL-Tamimi SK¹, Hassali MA¹, Shafie AA¹, Alrasheedy AA^{2,1}, Universiti Sains Malaysia, Penang, Malaysia, ²Qassim University, Qassim, Saudi Arabia

HEALTH CARE USE & POLICY STUDIES - Drug/Device/Diagnostic Use & Policy

- PHP4 A4 **APPLICATION OF MULTI-CRITERIA DECISION ANALYSIS (MCDA) SCORING AS AN HTA METHODOLOGY FOR OFF-PATENT PHARMACEUTICALS (OPP) IN EMERGING MARKETS**
Brixner D¹, Maniadakis N², Kaló Z³, Hu S⁴, Johnston A⁵, Shen J⁶, Wijaya KE⁷, ¹Personalized Health Care, University of Utah Health Sciences Center, Salt Lake City, UT, USA, ²National School Of Public Health, Athens, Greece, ³Eötvös Loránd University, Budapest, Hungary, ⁴Fudan University, Shanghai, China, ⁵Queen Mary University of London, London, UK, ⁶Abbott Laboratories, Abbott Park, IL, USA, ⁷Abbott Laboratories, Allschwil, Switzerland
- PHP5 A5 **ARE US PRIVATE PAYERS' MEDICAL POLICIES INFLUENCED BY COCHRANE EVIDENCE?**
Singh A¹, Hussain S², Najmi AK^{2,1}, Independent Researcher, New Delhi, India, ²Faculty of Pharmacy, Jamia Hamdard, Hamdard University, New Delhi, India
- PHP6 A6 **'SEVERE ILLNESS INSURANCE' IN CHINA: IMPACT OF THE NEW COVERAGE ON ACCESS TO HEALTH CARE AND INNOVATIVE DRUGS**
Sherwin G, Akpınar P, Yap B, **Li X**, ICON plc, LONDON, UK
- PHP7 A7 **FREE ESSENTIAL MEDICINES THROUGH PUBLIC HEALTH FACILITIES IN NEPAL: A QUALITATIVE STUDY**
Acharya M¹, Dahal A², ¹University of Arkansas for Medical Sciences, Little Rock, AR, USA, ²The University of Toledo, Toledo, OH, USA
- PHP9 A8 **SUGGESTION ON CRITICAL ILLNESS INSURANCE IN CHINA**
Zhu L, Xu H, Cui X, Sanofi China, Shanghai, China
- PHP10 A9 **ONLINE PHARMACY REGULATION IN INDIA: A CROSS SECTIONAL SURVEY ON PERCEPTIONS OF HEALTH CARE STUDENTS/PROFESSIONALS**
Peringadi Vayalil M, Rajesh V, Rajan MS, Girish T, Manipal University, Manipal, Udupi Dist., India
- PHP11 A10 **DEVELOPMENT OF HOSPITAL FORMULARY IN JAPAN - CURRENT TRENDS AND ISSUES**
Hamashima Y¹, Hamashima C^{2,1}, ¹University of Tokyo Hospital, Tokyo, Japan, ²National Cancer Center, Tokyo, Japan
- PHP12 B1 **HOW DOES PRICING AND ACCESS OF INNOVATIVE ONCOLOGY AGENTS IN CHINA COMPARE WITH OTHER ASIAN MARKETS?**
Sherwin G, Akpınar P, Yap B, Lu V, Im Y, ICON plc, LONDON, UK
- PHP13 B2 **WHAT IMPACT IS THE EVOLVING HEALTH CARE LANDSCAPE HAVING ON ACCESS TO INNOVATIVE MEDICINES IN CHINA?**
Sherwin G, **Akpınar P**, Yap B, ICON plc, LONDON, UK
- PHP14 B3 **ASSESSMENT OF BIOSIMILAR LANDSCAPE IN KOREA, MALAYSIA, SINGAPORE AND TAIWAN**
Chen S¹, Conti CC², Cheong J¹, ¹GfK Singapore, Singapore, Singapore, ²GfK, London, UK
- PHP15 B4 **THE PRICING AND REIMBURSEMENT OF SPECIALTY DRUGS IN KEY ASIAN MARKETS**
Subramanian D, **Dummett H**, EMAX Solutions, Singapore, Singapore
- PHP16 B5 **BUILDING INTENTIONS WITH THE THEORY OF PLANNED BEHAVIOUR: THE MEDIATING ROLE OF KNOWLEDGE AND EXPECTATIONS IN SUCCESSFUL NEW PHARMACY PUBLIC HEALTH SERVICES IMPLEMENTATION**
Hoay TL¹, Hassali MA¹, Gan V², **Saleem F**¹, ¹Universiti Sains Malaysia, Penang, Malaysia, ²Universiti Putra Malaysia, Serdang, Malaysia
- PHP17 B6 **GENERAL PUBLIC KNOWLEDGE AND AWARENESS ABOUT MEDICINES USE IN PENANG, MALAYSIA**
Dawood OT, Hassali MA, Saleem F, Universiti Sains Malaysia, Penang, Malaysia
- PHP18 B7 **QUINOLONES UTILIZATION IN TWO TERTIARY HOSPITALS IN NIGERIA; A PHARMACOEPIDEMIOLOGICAL SURVEY**
Ogbonna B¹, Eze L¹, Ogbonna C², Ejim C^{2,1}, ¹NNAMDI AZIKIWE UNIVERSITY, ANAMBRA STATE, Nigeria, ²ENUGU STATE

UNIVERSITY TEACHING HOSPITAL, ENUGU, NIGERIA, ENUGU, Nigeria

PHP19 B8 ATTITUDE TOWARDS THE USE OF COMPLEMENTARY AND ALTERNATIVE MEDICINES (CAM) AMONG PHARMACY AND MEDICAL STUDENTS. A COMPARATIVE STUDY

Farooqui M¹, Othman CN¹, Sadeeqa S², Farooqui MA³, ul Haq N⁴,¹Universiti Teknologi MARA (UiTM), Kepala Batas, Malaysia, ²Institute of Pharmacy, Lahore, Pakistan, ³Kolej Universiti Insaniah, Kuala Ketil, Kedah,, Malaysia, ⁴University of Balochistan, Quetta, Pakistan

PHP20 B9 DRUG UTILIZATION IN AN OUTPATIENT PRIVATE PAEDIATRIC SETTING: AN OBSERVATIONAL STUDY

Deshwal S¹, Tiwari P¹, Kumar N²,¹National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar (Mohali), Punjab, India, ²Chaitanya Hospital, Chandigarh, India

PHP21 B10 DRUG UTILIZATION STUDY OF ANTIBIOTICS IN A SECONDARY CARE REFERRAL HOSPITAL

Rathikanti V,chalapathi institute of pharmaceutical sciences, Vijayawada, India

PHP22 C1 PERLIMINARY STUDY OF MEDICATION REGIMEN COMPLEXITY AMONG TAIWANESE ELDERLY WHO HAVE USED ANXIETY OR HYPNOTICS PRESCRIPTIONS

Chen J¹, Simonavice CA², Chen Y², Lin H¹,¹China Medical University, Taichung, Taiwan, ²China Medical University Hospital, Taichung, Taiwan

PHP23 C2 WHAT DO WE PAY FOR COMPOUNDED DRUGS?

Lin T¹, Tran DM², Shoair OA², Huang W¹, Cao V¹, Wilson L²,¹UCSF, San Francisco, CA, USA, ²University of California, San Francisco, San Francisco, CA, USA

PHP24 C3 A NATIONWIDE SURVEY ON INFECTION CONTROL ACTIVITIES WITHIN HOSPITALS ALLOWED TO IMPLEMENT PREFERENTIAL INFECTION PREVENTION COUNTERMEASURE FEE IN JAPAN

Hirose M¹, Nishimura N², Naora K², Imanaka Y³,¹Shimane University, Izumo, Japan, ²Shimane University Hospital, Izumo, Japan, ³Kyoto University, Kyoto, Japan

PHP25 C4 ASSOCIATION OF SOCIOECONOMIC CONDITIONS AND DRUG OFFENCES AND REINCARCERATION

Huang C, Yang M,National Taiwan University, Taipei, Taiwan

PHP26 C5 ASSESSMENT OF PRESCRIBING INDICATORS IN PUBLIC AND PRIVATE PRIMARY HEALTH CARE FACILITIES IN INDONESIA

Yuniar Y, Susyanty AL, Sari ID,National Institute of Health Research and Development, Central Jakarta, Indonesia

HEALTH CARE USE & POLICY STUDIES - Equity and Access

PHP27 C6 A REVIEW OF PHARMECEUTICAL POLICIES IN RESPONSE TO ECONOMIC CRISIS AND SANCTIONS

Kheirandish M,Tehran university of medical sciences, tehran, Iran (Islamic Republic of)

PHP28 C7 EQUITY OF GOVERNMENT SUBSIDY IN HEALTH CARE: A CASE STUDY IN CHINA

Si L¹, Chen M², Palmer AJ³,¹University of Tasmaina, Hobart, Australia, ²Nanjing Medical Univeristy, Nanjing, China, ³Menzies Institute for Medical Research, Hobart, Australia

PHP29 C8 DEVELOPING HTA GUIDELINES FOR RARE DISEASE THERAPIES - AN INDUSTRY PERSPECTIVE

Taylor CB¹, Weston AR¹, Milliner C², Schulz S², Clark F³, Goodall A³, Brown A⁴, Chim L⁵, Kwasha D⁵, Quinn E⁶, McDonnell T⁷, Evans K⁸,¹Asia Pacific, Sydney, Australia, ²Shire, North Ryde, Australia, ³Sanofi Genzyme, Macquarie Park, Australia, ⁴Sanofi Australia, Macquarie Park, Australia, ⁵Alexion Pharmaceuticals Australasia, Frenchs Forest, Australia, ⁶Vertex Pharmaceuticals (Australia), St Leonards, Australia, ⁷A. Menarini Australia, Chatswood, Australia, ⁸BioMarin Pharmaceutical Australia, Crows Nest, Australia

HEALTH CARE USE & POLICY STUDIES - Formulary Development

PHP31 C9 WHAT'S NEW IN THE GUIDELINES FOR SUBMISSION OF DOSSIER FOR LISTING INTO THE MINISTRY OF HEALTH MEDICINES FORMULARY (MOHMF) ?

Low EV, Ramli A, Lajis R, Aryani Md Yusof F,Ministry of Health Malaysia, Petaling Jaya, Malaysia

PHP32 C10 TEMPERATURE, REAL TIME, ON SITE, POTENCY MONITORING STUDIES OF DIFFERENT BRANDS OF CEPHALEXIN TABLETS STORED IN HOSPITAL AND COMMUNITY PHARMACIES IN DIFFERENT PART OF KERALA

Kiron sS,academy of pharmaceutical sciences, kannur, India

HEALTH CARE USE & POLICY STUDIES - Health Care Costs & Management

PHP33 D1 CONSTRUCTION OF SYSTEM DYNAMICS MODEL FOR MEDICAL CARE SYSTEM OF JAPAN

Inoue S¹, Xu H², Maswana J², Kobayashi M¹,¹CRECON Medical Assessment Inc., Tokyo, Japan, ²University of Tsukuba, Tokyo, Japan

PHP34 D2 THE STUDY OF DRUG PRICE COMPRISON BETWEEN CHINA AND 14 OTHER COUNTRIES

Liu B¹, Su W², Mo Y¹,¹Department of Health Economics, School of Public Health, Fudan University, Shanghai, China, ²IHS Life Sciences, Washington, DC, USA

PHP35 D3 THE FIRST INDONESIAN HEALTH-RELATED QUALITY OF LIFE VALUATION STUDY: AN EQ-5D-5L VALUE SET

Purba FD¹, Hunfeld J¹, Iskandarsyah A², Fitriana TS³, Sadarjoen SS², Passchier J⁴, van Busschbach J¹,¹Erasmus MC,

Rotterdam, The Netherlands, ²Padjadjaran University, Jatinangor, Indonesia, ³YARSI University, Jakarta, Indonesia, ⁴VU University, Amsterdam, The Netherlands

- PHP36 D4 **COST VARIATIONS OF INPATIENT, DAYCARE AND OUTPATIENT HYSTEROSCOPY IN A TERTIARY-CARE HOSPITAL IN MALAYSIA**
Shabaruddin FH, Chai BS, Woo YL, Dahlui M, University of Malaya, Kuala Lumpur, Malaysia
- PHP37 D5 **SPIRALLING HEALTHCARE EXPENDITURE IN MALAYSIA: IS IT SUSTAINABLE?**
Perumal AK, B. Braun, KL, Malaysia
- PHP38 D6 **UNIVERSAL HEALTH COVERAGE IN COUNTRIES ACROSS EAST AND SOUTHEAST ASIA – ASSOCIATIONS BETWEEN HEALTH EXPENDITURE AND SERVICE PROVISION**
Evans JS, Wickstead RM, Hanman K, Steeves S, Costello Medical Consulting Ltd, Cambridge, UK
- PHP39 D7 **THE IMPACTS OF CASE PAYMENT IN RURAL HAINAN OF CHINA**
He L, **Yang L**, Peking University, Beijing, China
- PHP40 D8 **COSTS AND BENEFITS OF HOME FOOD INDUSTRY ISSUANCE PROGRAM IN INDONESIA**
Sucharya pK¹, **Sari K**², ¹Center for Health Research Universitas Indonesia, Depok, Indonesia, ²Center for Health Economics and Policy Studies Universitas Indonesia, Depok, Indonesia
- PHP41 D9 **EXPERIENCE SEEKING APPROPRIATE STANDARDS OF COST-EFFECTIVENESS RATIO: UPDATES AND CHALLENGES IN JAPANESE SETTING**
Kamae I, Sugimoto T, The University of Tokyo, Graduate School of Public Policy, Tokyo, Japan
- PHP42 D10 **ICT DIFFUSION AND PHARMACEUTICALS (ISSUES FOR DECISION TOOLS)**
Huttin CC, Endepusresearchinc and Univ Aix Marseille, Cambridge, MA, USA
- PHP43 E1 **APPLICATION LIMITATIONS OF COST MINIMIZATION ANALYSIS IN CHINA**
Zhu L, Cui X, Xu H, Sanofi China, Shanghai, China
- PHP44 E2 **RISK OF DISCONTINUATION OF ADVANCED THERAPY MEDICINAL PRODUCTS CLINICAL TRIALS**
Hanna E¹, Rémuzat C², Toumi M¹, ¹Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France, ²Creativ-Ceutical, Paris, France
- PHP45 E3 **OUTCOMES FROM HOMEOPATHIC PRESCRIBING IN SECONDARY CARE HOMEOPATHIC HOSPITAL: A PROSPECTIVE STUDY**
Dobariya N¹, Tiwari P¹, Dhiman K², Sareen P², Anand T², Sharda S², Manku Tk², Kaur R², ¹National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar (Mohali), Punjab, India, ²Homeopathic Medical College and Hospital, Chandigarh, India
- PHP46 E4 **HIGH-RISK MEDICATIONS AND UNPLANNED HOSPITALIZATIONS: A CASE-TIME-CONTROL STUDY**
Lin C¹, Wen Y², Chen L³, Hsiao F¹, ¹National Taiwan University, Taipei, Taiwan, ²Chang Gung University, Taoyuan, Taiwan, ³Taipei Veterans General Hospital, Taipei, Taiwan
- PHP47 E5 **IMPLEMENTATION OF ADVERSE EVENT TRIGGER TOOL SYSTEM FOR ASSESSING PATIENT SAFETY**
Vilakkathala R¹, Mallayasamy S¹, K V¹, Rodrigues GS², BH AR², ¹Manipal University, Manipal, India, ²Kasturba Medical College, Manipal, India
- PHP48 E6 **WHAT ARE THE KEY CONCERNS OF HEALTH CARE PROVIDERS IN CHINA? QUALITATIVE INVESTIGATION OF A DOUBLE-BLIND TELEPHONE SURVEY**
Sun Y¹, Liu GG¹, Wang T², You X¹, Zhao H¹, ¹Peking University, Beijing, China, ²Shenyang Pharmaceutical University, Shenyang, China
- PHP49 E7 **FACTORS ASSOCIATED WITH 90-DAY OR 180-DAY LONG-TERM USE OF ANXIETY-HYPNOTIC PRESCRIPTIONS AND ECONOMIC AND SAFETY OUTCOMES: A RETROSPECTIVE COHORT STUDY**
Lin H¹, Tsai H², Liu F³, Liao C⁴, Li C⁵, Lin C⁴, Chou C⁴, Chang C⁴, Simonavice CA⁴, Li T¹, ¹China Medical University, Taichung, Taiwan, ²Providence University, Taichung City, Taiwan, ³Hsuan Chuang University, Hsinchu City, Taiwan, ⁴China Medical University Hospital, Taichung, Taiwan, ⁵China Medical University Hospital, Taichung, Taiwan
- PHP50 E8 **EFFECTIVENESS OF TRIGGER TOOLS TO DETECT ADVERSE DRUG EVENTS FROM DISCHARGE SUMMARIES: A RETROSPECTIVE STUDY**
Anburaj E¹, Vilakkathala R², Mallayasamy S², Stanley W², ¹Manipal College of Pharmaceutical Sciences, Manipal, India, ²Manipal University, Manipal, India
- PHP51 E9 **EVALUATION OF ATTITUDE AND PERCEPTION OF RETAIL PHARMACISTS TOWARDS PATIENT SAFETY**
Sivanandy P, Marikannan M, Tan Tyng W, Tan Wee L, Lim Chong Y, International Medical University, Kuala Lumpur, Malaysia
- PHP52 E10 **IN-LICENSING AS A BUSINESS STRATEGY FOR PHARMACEUTICAL COMPANIES: A FRAMEWORK FOR THE NIGERIAN INDUSTRY**
Keshi CB, UGSM-, Zug, Switzerland
- PHP53 F1 **A STUDY ON IDENTIFICATION, MONITORING AND MANAGEMENT OF ADVERSE DRUG REACTIONS IN A TERTIARY CARE HOSPITAL**

- PHP54 F2 **Vuduqu R**, Eluka vL, Konuru V, Sagar SV, Kachapuram rC, St. Peter's Institute of Pharmaceutical Sciences, Hanamkonda, India
CHRONIC PATIENTS ATTITUDES, BELIEFS, AND EXPERIENCES REGARDING POLYPHARMACY AND WILLINGNESS TO DEPRESCRIBE IN QUETTA
- PHP55 F3 **ul Haq N**, Mohaib M, Nasim A, Razaque G, Riaz S, University of Balochistan, Quetta, Pakistan
PERSONALIZED ADAPTIVE REWARDS VERSUS INCENTIVES TO MOTIVATE SUSTAINABLE HEALTHY BEHAVIORAL CHANGE- A NEO-MASLOWIAN CONCEPTUAL MODEL
- PHP56 F4 **Jones CA**¹, Clark EM², Weintraub A¹, Zia A²,¹University of Vermont College of Medicine, Burlington, VT, USA, ²University of Vermont, Burlington, VT, USA
ADVERSE EVENTS ASSOCIATED WITH INTRAVENOUS IMMUNOGLOBULIN IN THAILAND
- PHP57 F5 **Sriphiromya P**, Ministry of Public Health, Nonthaburi, Thailand
A STUDY OF PRESCRIPTION PATTERN OF NON STEROIDAL ANTI-INFLAMMATORY DRUGS IN A TERTIARY CARE HOSPITAL
- PHP58 F6 **Thiruvengadarajan V**¹, Thattakudian Sheikuduman MS², Chakka G², Ramkanth S¹,¹Annamacharya College of Pharmacy, Kadapa, India, ²Annamacharya College of Pharmacy, YSR Kadapa, India
THE 2012 UPDATED BEERS CRITERIA IN FALLS RELATED HOSPITALIZATION IN OLDER ADULTS
- PHP59 F7 **Chen LL**, Ng HT, Siow B, Ong KY, Tay JY, Cheen HH, Lim YL, Mamun K, Singapore General Hospital, Singapore, Singapore
EFFECT OF CLINICAL PHARMACIST IN PATIENT SAFETY: A PROSPECTIVE INTERVENTIONAL STUDY
- PHP60 F8 **Nafis MA**, D Acharya L, Hande HM, Manipal University, Manipal, Udupi, India
THE EMERGING ROLES OF PHARMACISTS IN SELECTED TERTIARY HOSPITALS IN PANGASINAN AND LA UNION: FOCUS ON PHARMACEUTICAL CARE AND PHARMACOVIGILANCE
- PHP61 F9 **Cabral RP**, Pangasinan State University, Urdaneta City, Philippines
A PROSPECTIVE ANALYSIS OF ADVERSE DRUG REACTION IN A TERTIARY CARE HOSPITAL
- PHP62 F10 **Ramesh S**¹, Prashant C¹, KrishnaPrabha C², Jai Ganesh KP¹, Manikandhan C¹, Sivakumar P¹, Sivasankar M²,¹Nehru College of Pharmacy, Thrissur District, India, ²National College of Pharmacy, Kozhikode, India
DRUG UTILIZATION EVALUATION OF ANTIBIOTICS IN GENERAL MEDICINE DEPARTMENT OF A TERTIARY CARE HOSPITAL
- PHP63 G1 **Gowthami B**¹, Spurthi T²,¹JNTU, Anmantapur, kurnool, India, ²CES college of pharmacy, kurnool, India
REFORM OF CHINESE STATE-OWNED ENTERPRISE-AFFILIATED HOSPITAL
- PHP64 G2 **Wang T**¹, Li SC², Liu GG³, Wu Z¹, Sun Y³,¹Shenyang Pharmaceutical University, Shenyang, China, ²The University of Newcastle, Newcastle, Australia, ³Peking University, Beijing, China
ASSESSMENT OF CRITERIA INFLUENCES ON JUDICIOUS SELECTION OF NEW DRUG FOR FUTURE COVERAGE POLICY IN IRAN: AN ANALYSIS WITH STRUCTURAL EQUATION MODELING
- PHP65 G3 **Viyanchi A**, Niasti F, Rabani T, Hamadan University of medical sciences, Hamadan, Iran
CONSOLIDATION OF CHINA'S TWO BASIC MEDICAL INSURANCE PROGRAMS: UNDERSTANDING NEW OPPORTUNITIES FOR ACCESS
- PHP66 G4 **MI M**¹, Suponcic S², LIU Y¹,¹Navigant Life Sciences, Shanghai, China, ²Navigant Life Sciences, Lawrenceville, NJ, USA
IS THE LACK OF INCLUSION ON THE NATIONAL DRUG REIMBURSEMENT LIST THE END OF THE WORLD FOR ACCESS?
- PHP67 G5 **MI M**¹, Suponcic S², LIU Y³,¹Navigant Life Science, Shanghai, China, ²Navigant Life Sciences, Lawrenceville, NJ, USA, ³Navigant Life Sciences, Shanghai, China
IMPROVING ACCESS TO NEW ONCOLOGY DRUGS IN THE CHINA MARKET: SHORT TIME-TO-MARKET AND IMPROVE AFFORDABILITY
- PHP68 G6 **LIU Y**¹, Suponcic S², MI M¹,¹Navigant Life Sciences, Shanghai, China, ²Navigant Life Sciences, Lawrenceville, NJ, USA
PATIENT ACCESS TO HIGH-COST AND HIGH-VALUE SPECIALTY PRODUCTS IN CHINA: REVIEW OF DECISIONS FROM ZHEJIANG, NEIMENGGU, SHANDONG AND JIANGXI
- PHP69 G7 **Gambari J**, Chowdhury CA, Duttagupta S, Yang M, CBPartners, New York, NY, USA
UPCOMING REGULATIONS ON INSURANCE REIMBURSEMENT STANDARD IN CHINA: CHALLENGES AND OPPORTUNITIES FOR MNCS
- PHP70 G8 **MI M**¹, Suponcic S², Wang M³, LIU Y¹,¹Navigant Life Sciences, Shanghai, China, ²Navigant Life Sciences, Lawrenceville, NJ, USA, ³Navigant Life Sciences, London, UK
A CASE STUDY ON THE DEVELOPMENT, IMPLEMENTATION AND OUTCOME OF CRITICAL DISEASE INSURANCE IN SHEN ZHEN, CHINA
- PHP71 G9 **Jiang J**, Jinan University, Guangzhou, China
TITLE: ACCESS TO ORPHAN AND ULTRA-ORPHAN DRUGS IN CHINA
- Gambari J**, Yang M, Chowdhury CA, Duttagupta S, CBPartners, New York, NY, USA

PHP72 G10 **HOW MUCH DO THE INSURED CITIZENS KNOW ABOUT THE PERSONAL ACCOUNT OF CHINA'S URBAN EMPLOYEES' BASIC MEDICAL INSURANCE AND WHAT ARE THEIR NEEDS? EVIDENCE FROM GUIZHOU, CHINA**

Wu H¹, Yi L², Ran X¹,¹Guizhou Medical University, Guiyang, China, ²Department of human resources and social security of Guizhou province, Guiyang, China

PHP73 H1 **THE ROLE OF ECONOMIC EVIDENCE IN DRUG REIMBURSEMENT: SOUTH KOREA**

Bae E¹, Lee H², Kwon H³, Yang B⁴,¹Gyeongsang National University, Jinju, South Korea, ²National Health Insurance Service, Seoul, South Korea, ³Mokwon University, Daejeon, South Korea, ⁴Seoul National University, Seoul, South Korea

HEALTH CARE USE & POLICY STUDIES - Health Care Research & Education

PHP74 H2 **EVALUATING THE RELATIVE EFFECTIVENESS OF TWO MALNUTRITION RISK ASSESSMENT TOOLS IN SURGICAL POPULATION AT A TERTIARY CARE HOSPITAL IN MALAYSIA**

Khan OH¹, Khan AH¹, Zakaria AD², Hashim MN², Sulaiman SA¹,¹Universiti Sains Malaysia, Pulau Penang, Malaysia, ²Universiti Sains Malaysia, Kota Bharu, Malaysia

PHP75 H3 **VALUING HEALTH: RESULTS FROM THE HEALTH AUCTION VALUATION EXPERIMENT (HAVE) STUDY**

Byrnes J¹, Kularatna S¹, Scuffham P²,¹Griffith University, Meadowbrook, Australia, ²Griffith University, Gold Coast, Australia

PHP76 H4 **THE STUDY OF THE EFFECT OF PHARMACY MANAGER'S MANAGERIAL SKILLS ON THE PERFORMANCE OF COMMUNITY PHARMACIES OF TEHRAN**

Sehat S¹, Mirjamali F², Rangchian M³, Mehralian G⁴, Salamazadeh J⁵,¹Islamic Azad University, Tehran, Iran (Islamic Republic of), ²Shahid Beheshti University of Medical Sciences, Pharmacy School, Tehran, Iran (Islamic Republic of), ³Shahid Beheshti University of Medical Sciences, School of Pharmacy, Tehran, Iran, ⁴Shahid Beheshti university of medical sciences, School of Pharmacy, Tehran, Iran, ⁵Shahid Beheshti University of Medical Sciences, School of Pharmacy, Tehran, Iran

PHP78 H5 **PREDICTIVE VALIDITY OF NATIONAL NOSOCOMIAL INFECTION SURVEILLANCE (NNIS) AND STUDY ON THE EFFICACY OF NOSOCOMIAL INFECTIONS (SENIC) RISK INDEXES FOR THE INCIDENCE OF SURGICAL SITE INFECTIONS (SSI) IN GENERAL SURGERY AT HOSPITAL UNIVERSITI SAINS MALAYSIA (HUSM)**

Khan OH¹, Zakaria AD², Hashim MN², Sulaiman SA¹, Khan AH¹,¹Universiti Sains Malaysia, Pulau Penang, Malaysia, ²Universiti Sains Malaysia, Kota Bharu, Malaysia

PHP79 H6 **ASSESSMENT OF COMMUNITY PHARMACY SERVICES IN MALAYSIA: PERSPECTIVES FROM COMMUNITY PHARMACISTS, GENERAL PRACTITIONERS, CONSUMERS AND HEALTH POLICY STAKEHOLDERS**

Ooi GS¹, Ahmad Hassali MA², Shafie AA³, Kong DC⁴, Mak V⁵, Chua GN²,¹AIMST Univeristy, Bedong, Kedah, Malaysia, ²Discipline of Social and Administrative Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia, ³Universiti Sains Malaysia, Penang, Malaysia, ⁴Monash University, Victoria, Australia, ⁵Monash University Malaysia, Selangor, Malaysia

PHP80 H7 **MEDICATION ERRORS AVOIDED BY MEDICATION RECONCILIATION PROCESS AT FEMALE SURGERY WARD IN RAMATHIBODI HOSPITAL, THAILAND**

Samarnkongsak T, Samankatiwat P, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

PHP81 H8 **EQ-5D UTILITY VALUE SETS FOR SRI LANKA: A CASE FOR ECONOMIC EVALUATIONS IN SOUTH ASIA**

Kularatna S¹, Byrnes J¹, Chen G², Scuffham P³,¹Griffith University, Meadowbrook, Australia, ²Flinders University, Adelaide, Australia, ³Griffith University, Gold Coast, Australia

PHP82 H9 **KNOWLEDGE, ATTITUDE AND PRACTICE (KAP) REGARDING BLOOD DONATION AMONG HEALTH CARE WORKERS IN MALAYSIA**

Farooqui MA¹, Yahaya BH², Hussien AR², Farooqui M³,¹Kolej Universiti Insaniah, Kuala Ketil, Kedah,, Malaysia, ²Universiti Sains Malaysia, Bertam, Malaysia, ³Universiti Teknologi MARA (Bertam campus), Penang, Malaysia

PHP83 H10 **HEALTH RELATED QUALITY OF LIFE FOR DISEASE POPULATION IN CHINA: A SYSTEMATIC REVIEW**

Zhou T¹, Guan HJ², Ma A¹, Liu GG³,¹China Pharmacuetical University, Nanjing, China, ²Peking University China Center for Health Economic Research, Beijing, China, ³Peking University, Beijing, China

PHP84 I1 **THE IMPACT OF DURATION ON EQ-5D-5L VALUE SETS DERIVED FROM A DISCRETE CHOICE EXPERIMENT**

Norman R¹, Mulhern B², Viney R², Bansback N³, Pearce A⁴,¹Curtin University, Perth, Australia, ²University of Technology Sydney, Sydney, Australia, ³University of British Columbia, Vancouver, BC, Canada, ⁴National Cancer Registry Ireland, Cork, Ireland

PHP85 I2 **USING BEST-WORST SCALING CHOICE EXPERIMENTS TO ELICIT THE MOST IMPORTANT DOMAINS OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN SINGAPORE**

Uy EJ¹, Bautista D², Xin X¹, Cheung YB², Thio S¹, Thumboo J¹,¹Singapore General Hospital, Singapore, Singapore, ²Duke-NUS Medical School, Singapore, Singapore

PHP86 I3 **TRENDS IN JAPANESE CLINICAL TRIAL REGISTRATION FROM 2005 TO 2014**

Sasaki M¹, Fukuda T², Shiroiwa T², Igarashi A³, Sato H¹,¹National Institute of Public Health, Wako,, Japan, ²National Institute of Public Health, Wako, Japan, ³University of Tokyo, Graduate School of Pharmaceutical Sciences, Tokyo, Japan

PHP87 I4 **A PUBMED BASED SEARCH ON COST EFFECTIVENESS AND HEALTH-RELATED QUALITY OF LIFE STUDIES WITH RESPECT TO COMPLEMENTARY AND ALTERNATIVE MEDICINES**

Bhat B¹, Sreedhar D¹, **Udupa N**^{2,1} Manipal College of Pharmaceutical Sciences, Manipal, India, ²Manipal University, Manipal, India

- PHP88 I5 DEVELOPING ITEM POOLS FOR PHYSICAL FUNCTIONING, SOCIAL RELATIONSHIPS, AND POSITIVE MINDSET TO MEASURE HEALTH-RELATED QUALITY OF LIFE (HRQL) IN THE SINGAPORE POPULATION**
Uy EJ¹, Xiao Y¹, Yeo PT¹, Xin X¹, Pua Y¹, Lee GL², Kwan YH³, Vaingankar JA⁴, Subramaniam M⁴, Chan MF⁵, Kumar N⁵, Bautista D³, Ow MY³, Lim PA¹, Choo BE¹, Leung YY¹, Chan A³, Sung SC³, Kwek TC¹, Cheung YB³, Thumboo J¹,¹Singapore General Hospital, Singapore, Singapore, ²National University of Singapore, Singapore, Singapore, ³Duke-NUS Medical School, Singapore, Singapore, ⁴Institute of Mental Health, Singapore, Singapore, ⁵Health Promotion Board, Singapore, Singapore
- PHP89 I6 COMPARISON BETWEEN THE EQ-5D-5L AND THE EQ-5D-3L FOR GENERAL POPULATION IN CHINA**
Zhou T¹, Guan HJ², Ma A¹, Liu GG³,¹China Pharmaceutical University, Nanjing, China, ²Peking University China Center for Health Economic Research, Beijing, China, ³Peking University, Beijing, China
- PHP90 I7 BUILDING INTENTIONS WITH THE THEORY OF PLANNED BEHAVIOUR: THE MEDIATING ROLE OF KNOWLEDGE AND EXPECTATIONS IN IMPLEMENTING NEW PHARMACEUTICAL SERVICES IN MALAYSIA**
Tan CL¹, Gan VB², Saleem F³, Hassali MA³,¹Ministry of Health Malaysia, Seremban, Malaysia, ²Universiti Putra Malaysia, Serdang, Malaysia, ³School of pharmaceutical sciences, Universiti Sains Malaysia, Penang, Malaysia
- PHP91 I8 INDICATORS IN EVALUATING FINANCIAL AND ECONOMIC PERFORMANCE OF PHARMACY: A SYSTEMATIC REVIEW**
Imani DA, Golestani M, Moghimi M, Janati A, Tabriz University of medical Sciences, Tabriz, Iran
- PHP92 I9 ASSESSMENT OF HEALTH RELATED QUALITY OF LIFE OF HOSPITAL ADMITTED PATIENTS IN TERTIARY CARE HOSPITALS QUETTA BY USING SF-12 QUESTIONNAIRE**
ul Haq N, Ali T, Nasim A, Razaq G, Riaz S, Yasmin R, University of Balochistan, Quetta, Pakistan
- PHP93 I10 EVALUATION OF THE DIFFERENT PHARMACOECONOMIC MODELS ACROSS THE WORLD: A COMPARATIVE STUDY**
Kotlo A, Muragundi PM, MCOPS Manipal University, Manipal, India
- PHP94 J1 DEVELOPING A COMPREHENSIVE, CULTURALLY SENSITIVE CONCEPTUAL FRAMEWORK OF HEALTH DOMAINS IN SINGAPORE**
Uy EJ¹, Ow MY², Xin X¹, Sung SC², Cheung YB², Bautista D², Thumboo J¹,¹Singapore General Hospital, Singapore, Singapore, ²Duke-NUS Medical School, Singapore, Singapore
- PHP95 J2 HOW MUCH ARE CHINESE WILLING TO PAY FOR THE HEALTH IMPROVEMENT?**
Sun J, Sun L, Shenyang Pharmaceutical University, Shenyang, China
- PHP96 J3 MY OPINIONS MATTER! HOW PERSPECTIVES, KNOWLEDGE AND EXPECTATIONS MATTER IN MODERATING THE SUCCESS OF NEW PHARMACEUTICAL SERVICES IMPLEMENTATION IN MALAYSIA**
Tan CL¹, Gan VB²,¹Ministry of Health Malaysia, Seremban, Malaysia, ²Universiti Putra Malaysia, Serdang, Malaysia
- PHP98 J4 HEALTH STATE VALUATION IN SRI LANKA USING THE EQ-5D-3L; PRECURSOR TO QALY ESTIMATION IN SOUTH ASIA**
Kularatna S¹, Scuffham P²,¹Griffith University, Meadowbrook, Australia, ²Griffith University, Gold Coast, Australia
- PHP99 J5 BILIRUBIN AND NEURODEGENERATIVE DISEASE PREVENTION**
Muhsain SN¹, Farooqui M¹, Lang M², Abu Bakar A²,¹Universiti Teknologi MARA, Kepala Batas, Malaysia, ²University of Queensland, Coopers Plains, Australia
- PHP100 J6 A COMPARATIVE ANALYSIS ON HEALTH SECURITY SYSTEM BETWEEN CHINA AND DEVELOPED COUNTRIES**
Wu J¹, Liu J², Zhu B², Mao Y²,¹City University of Hong Kong, Kowloon, Hong Kong, ²Xi'an Jiaotong University, Xi'an, China
- PHP101 J7 EVALUATION OF ANTIBACTERIAL AND CYTOTOXIC EFFECTS OF GYMNEMA SYLVESTRE R.BR. SPECIES CULTIVATED IN PAKISTAN AGAINST COMMON RESISTANT PATHOGENS**
Tahir M¹, Anjum MS², Zahid Tanveer M¹, Iqbal MZ³,¹University of Veterinary and Animal Sciences, Lahore, Pakistan, Lahore, Pakistan, ²PMAS- Arid Agriculture University, Rawalpindi, Pakistan, Rawalpindi, Pakistan, ³AIMST University, Sungai Petani, Malaysia
- PHP102 J8 WHAT IS GOVERNMENT'S RESPONSIBILITY FOR CHINA'S UNIVERSAL HEALTH SECURITY? AN OUTLOOK FOR A NATIONAL HEALTH SECURITY SYSTEM**
Wu J, Liu J, Zhu B, Mao Y, Xi'an Jiaotong University, Xi'an, China
- PHP103 J9 APPLICATION OF HEALTHCARE FAILURE MODE & EFFECT ANALYSIS IN IMPROVING PATIENT EDUCATION AT AN OUTPATIENT DEPARTMENT OF A TERTIARY CARE HOSPITAL**
Devarakonda S, Armed Forces Medical College, pune, India
- PHP104 J10 TRENDS OF INCLUDING PHARMACOECONOMICS COURSE IN THE UNDERGRADUATE PHARMACY CURRICULUM**
Thomas D, Sundararaj KG, Shirwaikar A, Gulf Medical University, Ajman, United Arab Emirates
- PHP105 K1 THE IMPACT OF SURGICAL PROFESSIONAL EDUCATION: A REVIEW OF CLINICAL AND ECONOMIC OUTCOMES**
Bourcet A¹, Lim S², Metz L¹,¹Johnson & Johnson Medical Asia Pacific, Singapore, Singapore, ²Costello Medical Singapore Pte Ltd, Singapore, Singapore

- PHP106 K2 HEALTH TECHNOLOGY ASSESSMENT SUPPORTS EVIDENCE-BASED DECISION-MAKING IN THE CHANGI GENERAL HOSPITAL MARKETPLACE EXERCISE**
Pwee KH, Tong SC, Chow WL, Eastern Health Alliance, Singapore, Singapore
- PHP107 K3 ECONOMIC EVALUATION GUIDELINE FOR PHARMACEUTICALS AND MEDICAL DEVICES IN JAPAN**
Fukuda T¹, Igarashi A², Ishida H³, Ikeda S⁴, Saito S⁵, Sakamaki H⁶, Shimozuma K⁷, Shirowa T¹, Takura T⁸, Tomita N⁹, Noto S¹⁰, Fukuda H¹¹, Moriwaki K¹², Moriyama Y¹, Akazawa M¹³, ¹National Institute of Public Health, Wako, Japan, ²University of Tokyo, Graduate School of Pharmaceutical Sciences, Tokyo, Japan, ³Yamaguchi University, Ube, Japan, ⁴International University of Health and Welfare, Ohtawara, Japan, ⁵Okayama University, Okayama, Japan, ⁶Tokyo University of Science, Saitama, Japan, ⁷Ritsumeikan University, Kusatsu, Japan, ⁸Osaka University, Osaka, Japan, ⁹National Institute of Public Health, Saitama, Japan, ¹⁰Niigata University of Health and Welfare, Niigata, Japan, ¹¹Kyushu University, Fukuoka, Japan, ¹²Kobe Pharmaceutical University, Kobe, Japan, ¹³Meiji Pharmaceutical University, Tokyo, Japan
- PHP108 K4 A QUANTITATIVE ANALYSIS OF HEALTH TECHNOLOGY ASSESSMENT (HTA) AGENCIES FOR ATTRIBUTES DRIVING TRANSPARENCY OF THE ORGANIZATION: COMPARISON OF SIX ASIA-PACIFIC HTA AGENCIES**
Mazumder D¹, Kapoor A², Gwatkin N³, Medeiros C⁴, ¹Optum, Greater Noida, India, ²Optum Global Solutions, Noida, India, ³Geni Biopharma, Hampshire, UK, ⁴Optum Life Sciences, Minneapolis, MN, USA
- PHP109 K5 SEGMENTATION OF SEVEN ASIA-PACIFIC HEALTH TECHNOLOGY ASSESSMENT (HTA) AGENCIES INTO DIFFERENT EVOLUTIONARY HTA ARCHETYPES**
Mazumder D¹, Kapoor A², Gwatkin N³, Medeiros C⁴, ¹Optum, Greater Noida, India, ²Optum Global Solutions, Noida, India, ³Geni Biopharma, Hampshire, UK, ⁴Optum Life Sciences, Minneapolis, MN, USA
- PHP110 K6 DETERMINING CRITERIA AND WEIGHTS FOR PRIORITISING HEALTH TECHNOLOGIES BASED ON THE PREFERENCES OF THE GENERAL POPULATION: A NEW ZEALAND PILOT STUDY**
Sullivan T, Hansen P, University of Otago, Dunedin, New Zealand
- PHP111 K7 COMPARISON OF ECONOMIC EVALUATION GUIDELINES BETWEEN JAPAN AND OTHER COUNTRIES**
Millier A¹, Cheng X², Onishi Y³, Aballéa S¹, Toumi M¹, Doley J¹, ¹Creativ-Ceutical, Paris, France, ²Creativ-Ceutical, Hong Kong, Hong Kong, ³Creativ-Ceutical K.K., Tokyo, Japan
- PHP112 K8 LOCAL UTILITIES FOR LOCAL STUDIES: DATA AVAILABILITY AND METHODOLOGY IN JAPAN AND KOREA**
Kim HR¹, Chen X¹, Pyo J², Crawford B³, ¹IMS Japan KK, Minato-ku, Tokyo, Japan, ²IMS Health Korea, Seoul, South Korea, ³IMS Japan K.K., Minato-ku, Tokyo, Japan
- PHP113 K9 REVIEW OF PRICING & INNOVATION IN KOREA & TAIWAN**
Gambari J, Duttagupta S, Chowdhury CA, CBPartners, New York, NY, USA
- PHP114 K10 A BARRIERS TO AND FACILITATORS OF THE USE OF HTA REPORTS BY POLICYMAKERS IN KAZAKHSTAN**
Kostyuk A¹, Akanov A², Nurgozhin T³, ¹KazAHTA, Astana, Kazakhstan, ²Astana Medical University, Astana, Kazakhstan, ³Nazarbayev University, National Laboratory Astana, Astana, Kazakhstan
- PHP115 L1 TRENDS IN HEALTH TECHNOLOGY ASSESSMENTS SINCE THE INTRODUCTION OF COST-EFFECTIVENESS IN THE NETHERLANDS**
Dvortsin E, Vondeling G, van der Woude T, Postma MJ, University of Groningen, Groningen, The Netherlands

HEALTH CARE USE & POLICY STUDIES - Population Health

- PHP116 L2 SCIENTIFIC EPIDEMIOLOGY AND HEALTH ECONOMICS: A RETROSPECTIVE ANALYSIS ON PESTICIDE CONSUMPTION AND SURVIVORS IN TELANGANA STATE-INDIA**
Banoth SL, Kakatiya University, Warangal, India
- PHP117 L3 ESTIMATING THE CONTRIBUTION ON THE REDUCTION OF THE BURDEN OF IRON DEFICIENCY ANEMIA FROM THE CURRENT FORTIFICATION STRATEGY OF COMMERCIAL FOODS TARGETED TO INFANTS AND TODDLERS IN INDIA. SCENARIOS USING SYSTEMATIC REVIEW AND REAL WORLD EVIDENCE**
Detzel P, Nestle Research Center, Lausanne, Switzerland

HEALTH CARE USE & POLICY STUDIES - Prescribing Behavior & Treatment Guidelines

- PHP118 L4 HOW GIFTS AND BRAND REMINDERS INFLUENCE THE GENERIC BRAND SELECTION AMONG PHYSICIANS?**
Muragundi PM, Bharath K, Udupa N, Manipal University, Manipal, India
- PHP119 L5 EVALUATION OF SOCIAL SECURITY ORGANIZATION'(SSO) REGULATIONS ON PHYSICIAN PRESCRIBING PATTERN IN IRAN IN 2014**
Soleymani F¹, Kebriaeezadeh A², ¹Tehran University of Medical Sciences, Tehran, Iran (Islamic Republic of), ²Tehran University of Medical Sciences, Faculty of Pharmacy, Tehran, Iran (Islamic Republic of)
- PHP120 L6 USE OF CLINICAL INTELLIGENCE IN MONITORING RATIONAL DRUG USE INDICATORS IN THAILAND**
Phraewphiphat R, Piebpien P, Bunupuradah P, Pattanapruteep O, Leelaudomlapi S, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
- PHP121 L7 PROSPECTIVE STUDY OF THE INCIDENCE, NATURE AND CAUSES OF DISPENSING ERRORS IN COMMUNITY PHARMACIES OF ULAANBAATAR, MONGOLIA**

HEALTH CARE USE & POLICY STUDIES - Quality of Care

PHP122 L8 **THE ACCURACY OF PATIENT SELF REPORT IN MEASURING CONTINUITY OF CARE IN AUSTRALIA**

Wright M, University Technology Sydney, Broadway, Australia

PHP123 L9 **MEDICATION RECONCILIATION: A TOOL FOR BETTER PATIENT CARE**

Vangaveti T¹, Karimkuttickal NM¹, P SK¹, P SK¹, Vilakkathala R², Mallayasamy S², Stanley W²,¹Manipal College of Pharmaceutical Sciences, Manipal, India, ²Manipal University, Manipal, India

HEALTH CARE USE & POLICY STUDIES - Regulation of Health Care Sector

PHP124 L10 **INTERNATIONAL REFERENCE PRICING'S EVOLUTION IN CHINA**

Guan Y, Sanofi China, Shanghai, China

PHP125 M1 **A COMPARISON OF NATIONAL GUIDELINES FOR NETWORK META ANALYSIS**

Laws AJ, Icon Plc, Vancouver, BC, Canada

HEALTH CARE USE & POLICY STUDIES - Risk Sharing/Performance-Based Agreements

PHP126 M2 **PRICING AND MARKET ACCESS OF ORPHAN DRUGS IN CHINA: ANALYSIS OF NATIONAL AND PROVINCIAL POLICY AND THE ASSOCIATED IMPACT ON COVERAGE**

Sherwin G, Akpinar P, Yap B, ICON plc, LONDON, UK

PHP127 M3 **DEVELOPMENT OF HTA IN KAZAKHSTAN**

Bektur C, Nazarbayev University, National Laboratory Astana, Astana, Kazakhstan

PHP128 M4 **ADOPTION OF MANAGED ENTRY AGREEMENTS IN ESTABLISHED AND EMERGING MARKETS**

Xue Y¹, Montilva J², Degun R¹,¹Navigant Consulting Inc, London, UK, ²Navigant Consulting, London, UK

PHP129 M5 **ANALYSIS ON THE REGIONAL DISTRIBUTION OF TELEMEDICINE IN CHINA**

Lu B, Shenyang Pharmaceutical University, shenyang, China, China

HEALTH CARE USE & POLICY STUDIES - Conceptual Papers

PHP130 M6 **A CONCEPTUAL FRAMEWORK FOR TACKLING MARKET ACCESS CHALLENGES IN ASIA**

Umareddy I, Kantar Health, Singapore, Singapore

PHP131 M7 **UNDERSTANDING CONTINUITY OF CARE AT A PROVIDER AND PRACTICE LEVEL**

Wright M, University Technology Sydney, Broadway, Australia

PHP132 M8 **NEED OF COSMETOVIGILANCE IN INDIA**

Udupa N, **Ligade V**, Manipal University, Manipal, India

PHP133 M9 **USE OF HEALTH ECONOMIC INFORMATION IN THE MANAGEMENT OF HEALTH CARE RESOURCE ALLOCATION**

Maharajan M¹, Rajiah K², Sivanandy P²,¹International Medical University Malaysia, Kuala Lumpur, Malaysia, ²International Medical University, Kuala Lumpur, Malaysia

PHP134 M10 **DO NUTRITION INTERVENTIONS REQUIRE A DIFFERENT APPROACH TO ECONOMIC EVALUATION?**

Drummond M¹, Fattore G²,¹University of York, Heslington, York, UK, ²SDA-Bocconi School of Management, Centre for Research in Healthcare Management (CERGAS), Milano, Italy

PHP135 N1 **A CONCEPTUAL FRAMEWORK OF BASELINE EQUITY FOR RURAL BASIC MEDICAL INSURANCE IN CHINA: BASED ON POLICY PROCESS THEORY**

Wu J, Liu J, Zhu B, Mao Y, Xi'an Jiaotong University, Xi'an, China

PHP136 N2 **PRACTICE BASED OUTCOME RESEARCH IN COMMUNITY PHARMACY**

Rajiah K, **Maharajan M**, Sivanandy P, International Medical University, Kuala Lumpur, Malaysia

DISEASE- SPECIFIC STUDIES

GASTROINTESTINAL DISORDERS - Clinical Outcomes Studies

PGI1 N3 **A SYSTEMATIC REVIEW AND META-ANALYSIS ON TOLERABILITY AND EFFICACY OF SOFOSBUVIR CONTAINING REGIMENS IN HEPATITIS C PATIENTS WITH STAGE 4-5 CHRONIC KIDNEY DISEASE**

Singhal R, Ahlawat R, Tiwari P, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar (Mohali), Punjab, India

PGI2 N4 **META-ANALYSIS OF THE EFFECTIVENESS ON PEGINTERFERON FOR CHRONIC HEPATITIS C**

Chen PY¹, Ma AX²,¹China pharmaceutical university, Nanjing, China, ²China Pharmaceutical University, Nanjing, China

GASTROINTESTINAL DISORDERS - Cost Studies

PGI3 N5 **HOSPITAL ADMISSIONS AND COSTS OF CROHN'S DISEASE IN NEW ZEALAND AND THE IMPACT OF ADALIMUMAB**

Milne RJ¹, Geary RB², Eglinton TW²,¹University of Auckland, Auckland, New Zealand, ²University of Otago at Christchurch, Christchurch, New Zealand

- PGI5 N7 TREATMENT COST ESTIMATION OF CHRONIC GASTRITIS CAUSED BY HELICOBACTER PYLORI**
Odsuren M¹, Sarantuya T², Undram L³,¹First Central Hospital of Mongolia, Ulaanbaatar, Mongolia, ²United Family Intermed Hospital, Ulaanbaatar, Mongolia, ³Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia
- PGI6 N8 A COST-UTILITY ANALYSIS OF DIFFERENT ANTIVIRAL MEDICINE REGIMENS IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1 in Iran**
Alavian SM¹, Nikfar S², Kebriaeezadeh A², Rezaei Hemami M³, Sanati E², **Keshavarz K**⁴,¹Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Tehran, Iran (Islamic Republic of), ²Tehran University of Medical Sciences, Faculty of Pharmacy, Tehran, Iran (Islamic Republic of), ³University of Glasgow, Glasgow, UK, ⁴Shiraz University of Medical Sciences, School of Management and Information Sciences, Shiraz, Iran (Islamic Republic of)

GASTROINTESTINAL DISORDERS - Patient-Reported Outcomes & Patient Preference Studies

- PGI7 N9 ESTIMATING UTILITIES FOR LIVER DISEASES USING STANDARD GAMBLE METHOD**
Jo M, Ock M, Lim SY, University of Ulsan College of Medicine, Seoul, South Korea
- PGI8 N10 A STUDY ON DRUG UTILIZATION AND DRUG RELATED PROBLEMS AMONG ANTI-ULCER PATIENTS ADMITTED IN TEACHING HOSPITAL**
Ramkanth S¹, Thattakudian Sheikuduman MS², Thiruvengadarajan V¹, Chakka G²,¹Annamacharya College of Pharmacy, Kadapa, India, ²Annamacharya College of Pharmacy, YSR Kadapa, India
- PGI9 O1 ESTIMATION OF WILLINGNESS TO PAY FOR A QUALITY-ADJUSTED LIFE YEAR ON A CURE**
Song HJ¹, **Lee E**²,¹SungKyunKwan University, Suwon, South Korea, ²Sungkyunkwan University, Suwon, South Korea

GASTROINTESTINAL DISORDERS - Health Care Use & Policy Studies

- PGI10 O2 THE FOLLOW-UP AND UTILIZATION OF DRUG TREATMENT FOR CHRONIC HBV/HCV PATIENTS WITH MAJOR PSYCHIATRIC DISEASES IN TAIWAN**
Tsai C, Chang C, Tang C, Lin Y, Lu S, Taipei Medical University, Taipei, Taiwan
- PGI11 O3 REAL LIFE DRUG UTILIZATION AND BIOLOGICS EFFECTIVENESS IN PATIENTS WITH CROHN'S DISEASE – A POPULATION-BASED STUDY IN TAIWAN**
Smulders M¹, Cheng C², Lien HP³, Liang H⁴, **Khalid JM**⁵, Kao Yang Y²,¹SmartAnalyst, New York, NY, USA, ²National Cheng Kung University, Tainan, Taiwan, ³Takeda Pharmaceuticals Taiwan, Ltd., Taipei, Taiwan, ⁴Takeda Development Center Americas, Inc, Deerfield, IL, USA, ⁵Takeda Development Centre Europe Ltd, London, UK
- PGI12 O4 POLICY EVALUATION ON “THE PAY-FOR-PERFORMANCE PROGRAM OF HEPATITIS B AND C” IN TAIWAN**
Lu S, Tang C, Lin Y, Tsai C, Taipei Medical University, Taipei, Taiwan
- PGI13 O5 THE ROLE OF INSULIN-LIKE GROWTH FACTOR-1 ON STEATOHEPATITIS**
Bulur O, Dal K, Ertugrul dT, Aydoğan Y, Beyan E, Karadag I, Ünsal O, keçiören research hospital ANKARA /TURKEY, Ankara, Turkey
- PGI14 O6 HEART RATE RECOVERY IN INFLAMMATORY BOWEL DISEASE (IBD)**
Ünsal O, Karakaya S, Bulur O, Dal K, Uzman M, Eser M, Aydogan Y, keçiören research hospital ANKARA /TURKEY, Ankara, Turkey
- PGI15 O7 KNOWLEDGE, ATTITUDE AND PRACTICE TOWARDS HEPATITIS B AMONG MEDICAL COLLEGE STUDENTS OF QUETTA, PAKISTAN**
ul Haq N¹, Malik Z¹, Nasim A¹, Riaz S¹, Mohammad G¹, Azhar S²,¹University of Balochistan, Quetta, Pakistan, ²Comsats Institute of Information Technology, Abbottabad, Pakistan

MENTAL HEALTH - Clinical Outcomes Studies

- PMH1 O8 CLINICAL OUTCOMES OF BIPOLAR DISORDER ON LONG-TERM TREATMENT WITH LITHIUM WITH OR WITHOUT MOOD STABILIZERS**
De Guzman GQ, Virgen Milagrosa University Foundation, San Carlos City, Pangasinan, Philippines
- PMH2 O9 PREVALENCE AND CHARACTERISTICS OF MENTAL DISORDERS AMONG HOSPITALIZED BREAST CANCER PATIENTS IN THE UNITED STATES**
Wang X, Xiao H, University of Florida, Gainesville, FL, USA
- PMH3 O10 CROSS-VALIDATION OF A 7-ITEM CLINICAL DECISION RULE FOR DETECTING PANIC-RELATED ANXIETY IN EMERGENCY MEDICINE PATIENTS**
Sung SC¹, Rush AJ¹, Earnest A², Lim LE³, Lim SH³, Ong ME³,¹Duke-NUS Medical School, Singapore, Singapore, ²Monash University, Melbourne, Australia, ³Singapore General Hospital, Singapore, Singapore
- PMH4 P1 SOMATIC SYMPTOMS IN PATIENTS WITH UNDIAGNOSED DEPRESSION: PREVALENCE AND HEALTH CARE UTILIZATION IN JAPAN**
Takahashi O, Ohde S, St. Luke's International University, Tokyo, Japan
- PMH5 P2 CLINICAL EFFECTIVENESS TELEPSYCHOTHERAPY FOR DEPRESSION DISORDER: A SYSTEMATIC REVIEW**
Park JJ¹, Kim S², Park D²,¹National Evidence-based Collaborating Agency, Seoul, South Korea, ²National Evidence-based

Healthcare Collaborating Agency, Seoul, South Korea

PMH6 P3 COMPARATIVE EVALUATION OF SAFETY, EFFICACY AND COGNITIVE PROFILE OF AMISULPRIDE AND OLANZAPINE IN SCHIZOPHRENIA PATIENTS- A PROSPECTIVE STUDY

Ramesh S, Sivakumar P, Prashant C, Sivasankar M, Manikandhan C, Jai Ganesh KP, Nehru College of Pharmacy, Thrissur District, India

PMH7 P4 PREVALENCE OF ANTICHOLINERGIC DRUG USE IN OLDER ADULTS WITH DEMENTIA

Ong YS, Fong TY, Chen LL, Chiang YY, Lim KW, Koh L, Mamun K, Singapore General Hospital, Singapore, Singapore

MENTAL HEALTH - Cost Studies

PMH8 P5 ESTIMATING THE ECONOMIC BURDEN OF TREATMENT RESISTANT DEPRESSION IN TAIWAN USING THE NHIRD

Klug J¹, Yu F², Chang C³, Juang H⁴, Wang M⁵, Fife D⁶, Liu C⁴, Wang BC⁷, ¹Janssen Asia Pacific, Kowloon, Hong Kong, ²Janssen Asia Pacific, Beijing, China, ³Chang Gung University, TaoYuan, Taiwan, ⁴Chang Gung Memorial Hospital, Tao-Yun, Taiwan, ⁵Janssen Taiwan, Taipei, Taiwan, ⁶Janssen, pharmaceutical company of Johnson and Johnson, Titusville, NJ, USA, ⁷Elysia Group Ltd, Taipei, Taiwan

PMH9 P6 ECONOMIC BURDEN OF SCHIZOPHRENIA IN CHINA: A LITERATURE REVIEW

Jia Y¹, Cheng X², Aballea S³, Dorey J³, Toumi M⁴, ¹Shenyang Pharmaceutical University, Shenyang, China, ²Creativ-Ceutical, Hong Kong, Hong Kong, ³Creativ-Ceutical, Paris, France, ⁴Aix-Marseille University, Marseille, France

PMH10 P7 THE ECONOMIC BURDEN OF SCHIZOPHRENIA IN MALAYSIA

Teoh SL¹, Chaiyakunapruk N¹, Chong HY¹, Aziz SA², Chemi N², Othman AR², Zaki NM², Vanichkulpitak P³, ¹Monash University Malaysia, Selangor, Malaysia, ²Hospital Kuala Lumpur, Kuala Lumpur, Malaysia, ³Silpakorn University, Nakhon Pathom, Thailand

PMH11 P8 ESTIMATED RANGE OF COST OF TREATMENT OF ADULT SCHIZOPHRENIA PATIENTS AT A TERTIARY HOSPITAL AS OF OCTOBER 2015

Abala AT, Bautista T, University of the Philippines-Philippine General Hospital, Manila, Philippines

PMH12 P9 A COST-EFFECTIVENESS ANALYSIS OF GUANFACINE EXTENDED-RELEASE TREATMENT IN PEDIATRIC ATTENTION-DEFICIT/HYPERACTIVITY DISORDER

Maeda S, Shimozuma K, Takeda Y, Ritsumeikan University, Kusatsu, Japan

PMH13 P10 AN ECONOMIC MODEL OF ADVANCE CARE PLANNING: A COST EFFECTIVE INTERVENTION FOR PEOPLE WITH DEMENTIA

Nguyen K, Griffith University, Brisbane, Australia

PMH14 Q1 COST-UTILITY ANALYSIS EVALUATING VORTIOXETINE VERSUS VENLAFAXINE XR AND AGOMELATINE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER IN TAIWAN

Brignone M¹, Atsou K¹, Reynaud-Mougin C², Chen W³, **Milea D**⁴, ¹Lundbeck SAS, Paris, France, ²H. Lundbeck A/S, Copenhagen, Denmark, ³Hoan Pharmaceuticals Ltd., Taipei, Taiwan, ⁴Lundbeck Singapore Pte Ltd, Singapore, Singapore

PMH15 Q2 REAL-WORLD HEALTH OUTCOMES, ECONOMIC IMPACTS, AND COST-EFFECTIVENESS OF A BEIJING MUNICIPAL GOVERNMENT FUNDED FREE-DRUG PROGRAM IN COMMUNITY SCHIZOPHRENIA PATIENTS IN BEIJING, CHINA

Yan F¹, Yang Y², Jia P³, Huang Q¹, Chen Y¹, Du F³, Yang Y³, **Chen W**³, ¹Beijing Anding Hospital of Capital Medical University, Beijing, China, ²Beijing Municipal Commission of Health and Family Planning, Beijing, China, ³Beijing Community Services Association, Beijing, China

PMH16 Q3 ESTIMATING THE ECONOMIC IMPACT DUE TO PRODUCTIVITY LOSSES OF DIABETES AND MAJOR DEPRESSIVE DISORDER IN SINGAPORE: HUMAN CAPITAL VERSUS FRICTION COST APPROACHES

Brooks-Rooney C¹, Griffiths M², Chen G¹, ¹Costello Medical Singapore Pte Ltd, Singapore, Singapore, ²Costello Medical Consulting Ltd, Cambridge, UK

MENTAL HEALTH - Patient-Reported Outcomes & Patient Preference Studies

PMH17 Q4 ASSESS THE MEDICATION ADHERENCE IN PATIENTS WITH SEVERE MENTAL ILLNESS ATTENDING PUBLIC TERTIARY CARE HOSPITALS OF QUETTA, PAKISTAN

ul Haq N¹, Ahmed N¹, Rasool G², Illyas M², Nasim A¹, ¹University of Balochistan, Quetta, Pakistan, ²Baluchistan Institute of Psychiatry and Behavioral Sciences, Quetta, Pakistan

PMH18 Q5 THE MEDICATION ADHERENCE IN SCHIZOPHRENIA MANAGEMENT BY USING SECOND GENERATION ANTIPSYCHOTICS IN TAIWAN: A POPULATION STUDY BASED ON NHIRD

Chung C¹, Tai TA², Chou KP², ¹Mackay Medical College, New Taipei City, Taiwan, ²IMS Health Taiwan, Taipei, Taiwan

PMH19 Q6 QUALITY OF LIFE MEASURED WITH EQ-5D IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER IN JAPAN

Sakurai K¹, Yoshimura K², Arima H³, ¹The University of Tokyo, Tokyo, Japan, ²Chiba University, Chiba, Japan, ³Shinagawa Ekimae Mental Clinic, Tokyo, Japan

PMH22 Q7 ASSESSMENT OF HEALTH RELATED QUALITY OF LIFE (HRQOL) OF PATIENTS WITH SEVERE MENTAL ILLNESS ATTENDING TERTIARY CARE PUBLIC HOSPITALS OF QUETTA, PAKISTAN

ul Haq N¹, Ahmed N¹, Rasool G², Illyas M², Nasim A¹, ¹University of Balochistan, Quetta, Pakistan, ²Baluchistan Institute of Psychiatry and Behavioral Sciences, Quetta, Pakistan

MENTAL HEALTH - Health Care Use & Policy Studies

- PMH23 Q8 IS THERE A DIFFERENCE IN PERCEPTION AND PRACTICE IN PHARMACOLOGICAL MANAGEMENT OF SCHIZOPHRENIA- A CROSS SECTIONAL SURVEY IN INDIA**
Gundugurti PR¹, Nagpal R², Sheth AS³, Narang P⁴, Gawande SJ⁴, Sharma S⁴, Klug J⁵,¹Asha Hospital, Hyderabad, India, ²Manobal Klinik, New Delhi, India, ³Unlimited Potentialities, Mumbai, India, ⁴Johnson & Johnson India Private Limited, Mumbai, India, ⁵Johnson & Johnson Hongkong, Kowloon, Hong Kong
- PMH24 Q9 ASIANS' MENTAL HEALTH STATUS IN A U.S. MIDWESTERN METROPOLIS, 2004 -2013**
Liu Y¹, Cai J², Okah FA³,¹University of Missouri–Kansas City, Kansas City, MO, USA, ²Kansas City Health Department, Kansas City, MO, USA, ³University of Missouri - Kansas City, Kansas City, MO, USA
- PMH25 Q10 TREATMENT RESISTANT DEPRESSION DEVELOPMENT FROM MAJOR DEPRESSIVE DISORDER: A CLAIMS DATABASE ANALYSIS IN JAPAN**
Tsukazawa SK¹, Fife D², Shimamoto K³, Mahlich J¹,¹Janssen Pharmaceuticals KK, Tokyo, Japan, ²Janssen, pharmaceutical company of Johnson and Johnson, Titusville, NJ, USA, ³MediStatLab, Tokyo, Japan
- PMH26 R1 EXERCISE AND FACTORS INFLUENCE MENTAL HEALTH OF UNDERGRADUATED STUDENTS AT BURAPHA UNIVERSITY IN 2014**
Phanudulkitti C, Nawkij P, Sungkaeo A, Thanmarak P, Auamnoy T, Burapha University, Chonburi, Thailand

SENSORY SYSTEMS DISORDERS - Clinical Outcomes Studies

- PSS1 R2 LONG-TERM FOLLOW-UP OF RANIBIZUMAB TREATED PATIENTS WITH MYOPIC CHOROIDAL NEOVASCULARIZATION FROM THE RADIANCE CLINICAL TRIAL IN FOUR EAST ASIAN COUNTRIES**
Skelly A¹, **Lara N**², Pedros M², Macfadden W³,¹Novartis Ireland Limited, Dublin, Ireland, ²IMS Health, Barcelona, Spain, ³Novartis Pharma AG, Basel, Switzerland

SENSORY SYSTEMS DISORDERS - Cost Studies

- PSS2 R3 SENSITIVITY ANALYSIS OF ANTIBIOTIC COST IN CHRONIC SUPPURATIVE OTITIS MEDIA PATIENTS IN SOUTH INDIA: A RETROSPECTIVE OBSERVATIONAL STUDY**
Kumar S¹, Jayachandran L¹, Kumar A¹, A S¹, R B²,¹Manipal University, Manipal, India, ²Manipal university, Manipal, India
- PSS3 R4 ANALYSIS OF TWO PRESSURE ULCER DRESSINGS FOR COST REDUCTION IN THE BRAZILIAN PUBLIC HEALTH SYSTEM**
Tolentino AC¹, Dick S², Amaya R³,¹Hospital Universitario Pedro Ernesto - UERJ/HUPE, Rio de Janeiro, Brazil, ²The College Of St. Scholastica, Duluth, MN, USA, ³Pediatric Wound Care & Laser Specialists, Houston, TX, USA
- PSS4 R5 APPLICATION OF VALUE OF INFORMATION ANALYSIS TO MINIMIZE DECISION RISK IN MALAYSIA**
Chong HY¹, Wu BC², Chaiyakunapruk N¹,¹Monash University Malaysia, Selangor, Malaysia, ²Ministry of Health Singapore, Singapore, Singapore

SENSORY SYSTEMS DISORDERS - Patient-Reported Outcomes & Patient Preference Studies

- PSS5 R6 BARRIERS TO INTRAVITREAL INJECTION THERAPY ADHERENCE IN DME PATIENTS IN AUSTRALIA**
Schnabel R¹, Tan J², Cullip T³, Guinan G³, Cameron C¹,¹Allergan Australia Pty Ltd, Gordon, Australia, ²Allergan Pte Ltd, Singapore, Singapore, ³So What Research Pty Ltd, Potts Point, Australia
- PSS6 R7 ASSESSING THE OUTCOMES OF PROSTHETIC TREATMENT IN LOWER OVERDENTURE WEARERS**
Kordiyak A, Bratus-Hrynkyiv R, Danylo Halytskyi Lviv National Medical University, Lviv, Ukraine
- PSS7 R8 PREDICTED DEMAND FOR A NEW INJECTABLE SOLUTION FOR DELIVERING GLAUCOMA MEDICINE**
Ozdemir S¹, Wong T², Finkelstein EA³,¹Duke-NUS Medical School, Singapore, Singapore, ²Singapore National Eye Centre, Singapore, Singapore, ³Duke NUS Medical School, Singapore, Singapore
- PSS8 R9 Fabrication and Characterization of Anti-Vitiligo Cream containing 5% Hydroalcoholic Extract of Psoralea Corylifolia.**
Hussain I¹, Hussain N², Manan A¹, Ali B³, Rashid A⁴,¹SMBB Medical University, Larkana, Larkana, Pakistan, ²BZU, Multan, Multan, Pakistan, ³Gomal University, Dera Ismail Khan, Pakistan, ⁴DRAP Pakistan, Islamabad, Pakistan
- PSS9 R10 THE EFFECT OF TRADITIONAL MEDICINE ON QUALITY OF LIFE IN PATIENTS WITH ATOPIC DERMATITIS: A REVIEW OF RECENT CLINICAL TRIALS**
Ko Y, Cheon C, Jang B, Ko S, Kyung Hee University, Seoul, South Korea

SENSORY SYSTEMS DISORDERS - Health Care Use & Policy Studies

- PSS10 S1 DRUG UTILIZATION EVALUATION OF AMOXICILLIN-CLAVULANIC ACID IN CSOM PATIENTS IN A SOUTH INDIAN HOSPITAL: A RETROSPECTIVE ANALYSIS**
Jayachandran L¹, Kumar A¹, Kumar S¹, R B², A S¹,¹Manipal University, Manipal, India, ²Manipal University, Udipi, India
- PSS11 S2 ANTIMICROBIAL SUSCEPTIBILITY PATTERN IN CHRONIC SUPPURATIVE OTITIS MEDIA PATIENT IN A TERTIARY CARE HOSPITAL**
Kumar A¹, Jayachandran L¹, Kumar S², R B³, A S²,¹Manipal university, Manipal, udipi, India, ²Manipal University, Manipal, India, ³Manipal university, Manipal, India

URINARY/KIDNEY DISORDERS - Clinical Outcomes Studies

- PUK1 S3 BURDEN OF CHILDHOOD ONSET CHRONIC KIDNEY DISEASE**
Hsu C¹, Tain Y²,¹Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, ²Kaohsiung Chnag Gung Memorial Hospital, Kaohsiung, Taiwan
- PUK2 S4 CLINICAL EFFECTIVENESS OF CARBAPENEM VERSUS ALTERNATIVE ANTIBIOTICS FOR URINARY TRACT INFECTION DUE TO ENTEROBACTERIACEAE PRODUCING ESBL: A SYSTMATIC REVIEW**
Park JJ¹, Rhee J², Park D²,¹National Evidence-based Collaborating Agency, Seoul, South Korea, ²National Evidence-based Healthcare Collaborating Agency, Seoul, South Korea
- PUK3 S5 ETIOLOGY AND OUTCOME OF ACUTE KIDNEY INJURY IN SOUTH INDIAN POPULATION**
Zabiuddin Ahad M¹, Suresh AA¹, Kumar P¹, Attur RP²,¹Manipal College of Pharmaceutical Sciences, Manipal, India, ²Department of Nephrology, Kasturba Medical College, Manipal University, Manipal, India
-

URINARY/KIDNEY DISORDERS - Cost Studies

- PUK4 S6 ESTIMATING THE COST OF END-STAGE RENAL DISEASE TO THE HOSPITAL SYSTEM IN SINGAPORE**
Sidharta SD¹, Yang F², Yoong JS¹,¹National University of Singapore, Singapore, Singapore, ²University of Manchester, Manchester, UK
- PUK5 S7 COMPARATIVE ANALYSIS ON THE OUT-OF-POCKET EXPENDITURE AMONG PATIENTS SUFFERING FROM CHRONIC KIDNEY DISEASE BETWEEN MEDICAL INSURANCE COVERED AND UNCOVERED AREAS IN CHINA**
Wu J, Liu J, Zhu B, Mao Y,¹Xi'an Jiaotong University, Xi'an, China
- PUK6 S8 PHARMACOECONOMIC EVALUATION OF PATIENTS UNDERGOING HEMODIALYSIS AT A TERTIARY CARE CENTRE**
Prasad S, Kaza S, Prasad N S, Prabhu RA, Rangaswamy D, Shenoy S, Saraf K,¹Kasturba Medical College Manipal, Manipal University, Manipal, Udupi, Karnataka, India
- PUK7 S9 COST-EFFECTIVENESS OF A COMBINATION OF RENIN-ANGIOTENSIN SYSTEM INHIBITORS (RAS)/CALCIUM CHANNEL BLOCKERS (CCB) OR RAS MONOTHERAPY TO RETARD PROGRESSION OF KIDNEY DISEASE IN MALAYSIA**
Mohd Tahir NA¹, Thomas P², Makmor Bakry M³, Abdul Gafor AH⁴, Li SC¹,¹University of Newcastle, Callaghan, NSW, Australia, ²Taylor's University, Selangor, Malaysia, ³Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia, ⁴Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia
- PUK8 S10 COST EFFECTIVENESS OF OVERACTIVE BLADDER TREATMENT WITH MIRABEGRON IN PATIENTS IN SOUTH KOREA**
Suh D¹, Lee S¹, Lim SJ¹, Song J¹, Ko G²,¹Chung-Ang University, Seoul, South Korea, ²Astellas Pharma Inc., Seoul, South Korea
-

URINARY/KIDNEY DISORDERS - Patient-Reported Outcomes & Patient Preference Studies

- PUK10 T1 PATIENT ENGAGEMENT: TO SUPPORT MEDICATION ADHERENCE IN KIDNEY TRANSPLANTATION**
Low JK¹, Crawford K¹, Manias E², Williams A¹,¹Monash University, Clayton, Australia, ²Deakin University, Burwood, Australia
- PUK11 T2 LONGITUDINAL TRAJECTORIES OF DEPRESSIVE AND ANXIOUS SYMPTOMS FOLLOWING A SELF-MANAGEMENT INTERVENTION FOR HAEMODIALYSIS PATIENTS**
Lam KE¹, Mooppil N², Ng HJ¹, Kang AW¹, McBain H³, Newman S³, Griva K¹,¹Department of Psychology, Faculty of Arts and Social Sciences, National University of Singapore, Singapore, Singapore, ²National Kidney Foundation, Singapore, Singapore, Singapore, ³School of Health Sciences, City University London, London, UK
- PUK12 T3 PROGRESSION AND OUTCOMES OF NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE PATIENTS**
Khan YH¹, Sarriff A¹, Adnan AS², Khan AH¹, Mallhi TH³,¹Universiti Sains Malaysia, Pulau Pinang, Malaysia, ²University Sains Malaysia, Kota Bharu, Malaysia, ³University Sains Malaysia, Pulau Penang, Malaysia
- PUK13 T4 QUALITY OF LIFE FOR PATIENTS USING HEMODIALYSIS (HD) VS. PERITONEAL DIALYSIS (PD) MODALITIES IN TAIWAN**
Kuo C, Hsieh W, **Tang C**,¹Taipei Medical University, Taipei, Taiwan
-

URINARY/KIDNEY DISORDERS - Health Care Use & Policy Studies

- PUK14 T5 CLINICAL PROFILE AND MANAGEMENT OF CHRONIC KIDNEY DISEASE IN INDIAN GERIATRIC PATIENTS AT A PUBLIC TERTIARY CARE HOSPITAL: A CROSS-SECTIONAL STUDY**
Tiwari P¹, Ahlawat R¹, D'Cruz S²,¹National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar (Mohali), Punjab, India, ²Government Medical College & Hospital, Chandigarh, India
- PUK15 T6 MANAGEMENT AND OUTCOMES OF ACUTE KIDNEY INJURY**
Kumar P¹, Suresh AA¹, Ahad MZ¹, Attur RP²,¹Manipal College Of Pharmaceutical Sciences, Manipal, India, ²Department of Nephrology, Kasturba Medical College, Manipal University, Manipal, India
- PUK16 T7 STOCK REDUCTION OF ERYTHROPOIETIN FOR PATIENTS ON HEMODIALYSIS AT SOMDECH PHRA DEBARATANA MEDICAL CENTER**
Inmuanghiranchot S, Supapsophon P, Aim-oat A, Lohvithee P, Chandraruangnabha Y, Piluk W,¹Ramathibodi hospital, Bangkok, Thailand

